NCT06884098 A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284
| NCT ID | NCT06884098 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Addpharma Inc. |
| Condition | Primary Hypercholesterolaemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2025-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2025-03-10 with a primary completion date of 2025-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.
Eligibility Criteria
Inclusion Criteria: * Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit * The Age equal to or greater than 19 in healthy volunteers at the time of screening visit Exclusion Criteria: * Participation in other clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06884098 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Primary Hypercholesterolaemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06884098 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06884098 currently recruiting?
Yes, NCT06884098 is actively recruiting participants. Contact the research team at parkje@addpharma.co.kr for enrollment information.
Where is the NCT06884098 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06884098 clinical trial?
NCT06884098 is sponsored by Addpharma Inc.. The trial plans to enroll 60 participants.